Use of effectors of glutaminyl and glutamate cyclases

US7462599B2 · kind B2 · utility

Assignee

• PROBIODRUG AG · DE

Inventors

• Stephan Schilling · Halle (Saale), DE
• Torsten Hoffmann · Weil am Rhein, DE
• Andre Niestroj · Halle (Saale), DE
• Hans-Ulrich Demuth · Halle (Saale), DE
• Ulrich Heiser · Halle (Saale), DE

Key dates

• Filing date: Oct 15, 2004
• Grant date: Dec 9, 2008
• Expiry date: Jun 30, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.